These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

88 related articles for article (PubMed ID: 7910042)

  • 1. Hemofil-M study.
    Rocino A; de Biasi R
    Ann Hematol; 1994; 68 Suppl 3():S55-7. PubMed ID: 7910042
    [No Abstract]   [Full Text] [Related]  

  • 2. A 3.5-year study of immune function in persons with hemophilia infusing recombinant factor VIII.
    Brettler D
    Ann Hematol; 1994; 68 Suppl 3():S49-50. PubMed ID: 7910039
    [No Abstract]   [Full Text] [Related]  

  • 3. Clotting factors isolated with monoclonal antibodies.
    Gomperts ED
    Curr Stud Hematol Blood Transfus; 1991; (58):52-8. PubMed ID: 1954774
    [No Abstract]   [Full Text] [Related]  

  • 4. Monoclate-P--hemofil-M study.
    Seremetis S
    Ann Hematol; 1994; 68 Suppl 3():S45-7. PubMed ID: 7910038
    [No Abstract]   [Full Text] [Related]  

  • 5. Recombinate study.
    Gomperts E
    Ann Hematol; 1994; 68 Suppl 3():S51. PubMed ID: 7910040
    [No Abstract]   [Full Text] [Related]  

  • 6. Long-term surveillance studies of previously untreated and treated patients, virally uninfected and infected patients--impact on the immune and other systems.
    Poon MC
    Ann Hematol; 1994; 68 Suppl 3():S83-6. PubMed ID: 7910044
    [No Abstract]   [Full Text] [Related]  

  • 7. Immunological aspects of inhibitor development.
    Reding MT
    Haemophilia; 2006 Dec; 12 Suppl 6():30-5; discussion 35-6. PubMed ID: 17123391
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Single cell analysis of factor VIII-specific T cells in hemophilic mice after treatment with human factor VIII.
    Sasgary M; Ahmad RU; Schwarz HP; Turecek PL; Reipert BM
    Thromb Haemost; 2002 Feb; 87(2):266-72. PubMed ID: 11858486
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical experience with Hemofil M in a hemophilia patient exhibiting inhibitors.
    Ingerslev J; Wallevik K
    Ann Hematol; 1991 Sep; 63(3):152-4. PubMed ID: 1932291
    [No Abstract]   [Full Text] [Related]  

  • 10. Immune reconstitution inflammatory syndrome (IRIS) as a cause for inhibitor development in hemophilia.
    Werwitzke S; Tiede A; Stoll M; von Depka M
    J Thromb Haemost; 2004 Jan; 2(1):193-4. PubMed ID: 14717985
    [No Abstract]   [Full Text] [Related]  

  • 11. Inhibitor development and successful immune tolerance in an HIV-infected patient with haemophilia A and after immune reconstitution with HAART.
    Kruse-Jarres R; Hadi CM; Leissinger CA
    Haemophilia; 2007 Nov; 13(6):707-11. PubMed ID: 17973846
    [TBL] [Abstract][Full Text] [Related]  

  • 12. High purity factor VIII concentrates and HIV infection.
    Lee CA
    BMJ; 1992 Mar; 304(6827):641. PubMed ID: 1348441
    [No Abstract]   [Full Text] [Related]  

  • 13. Changes in T4/T8 ratio over a ten years period related to the factor VIII concentrates used in a group of HIV negative haemophiliacs.
    Smid WM; van der Meer J; Halie MR
    Thromb Haemost; 1995 Mar; 73(3):552-3. PubMed ID: 7667844
    [No Abstract]   [Full Text] [Related]  

  • 14. Changes in CD4 count relative to product usage: findings from the transfusion safety study.
    Hilgartner MW
    Semin Hematol; 1993 Oct; 30(4 Suppl 5):7-9. PubMed ID: 7903481
    [No Abstract]   [Full Text] [Related]  

  • 15. CD4 cells in HIV-1 infected hemophiliacs: effect of factor VIII concentrates.
    Goldsmith JM; Deutsche J; Tang M; Green D
    Thromb Haemost; 1991 Oct; 66(4):415-9. PubMed ID: 1839091
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Purity of factor VIII concentrates and serial CD4 counts. The Transfusion Safety Study Group.
    Hilgartner MW; Buckley JD; Operskalski EA; Pike MC; Mosley JW
    Lancet; 1993 May; 341(8857):1373-4. PubMed ID: 8098792
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Consistently normal CD4+, CD8+ levels in haemophilic boys only treated with a virally safe factor VIII concentrate (BPL 8Y).
    Evans JA; Pasi KJ; Williams MD; Hill FG
    Br J Haematol; 1991 Nov; 79(3):457-61. PubMed ID: 1751373
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Risks of immunodeficiency, AIDS, and death related to purity of factor VIII concentrate. Multicenter Hemophilia Cohort Study.
    Goedert JJ; Cohen AR; Kessler CM; Eichinger S; Seremetis SV; Rabkin CS; Yellin FJ; Rosenberg PS; Aledort LM
    Lancet; 1994 Sep; 344(8925):791-2. PubMed ID: 7916077
    [TBL] [Abstract][Full Text] [Related]  

  • 19. HIV infection and haemophilia.
    Jones P
    Arch Dis Child; 1991 Mar; 66(3):364-8. PubMed ID: 1902651
    [No Abstract]   [Full Text] [Related]  

  • 20. Effect of HIV-1 infection on CD4 cells in a hemophilia cohort.
    Green D; Deutsche J; Tang M; Goldsmith J
    Haematologica; 1990; 75 Suppl 5():132-41. PubMed ID: 1982277
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.